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Introduction: In patients with systemic sclerosis (SSc), associated pulmonary arterial hypertension (SSc-APAH) is the
leading cause of death. The objective of this prospective screening study was to analyse sensitivity and specificity
of stress Doppler echocardiography (SDE) in detecting pulmonary hypertension (PH).
Methods: Pulmonary artery pressures and further parameters of PH were assessed by echocardiography and right
heart catheterisation (RHC) at rest and during exercise in patients with SSc. Investigators of RHC were blinded to
the results of non-invasive measurements.
Results: Of 76 patients with SSc (64 were female and mean age was 58±14 years), 22 (29 %) had manifest PH
confirmed by RHC: four had concomitant left heart diseases, three had lung diseases, and 15 had SSc-APAH.
Echocardiography at rest missed PH diagnosis in five of 22 patients with PH when a cutoff value for systolic
pulmonary arterial pressure (PASP) was more than 40 mm Hg at rest. The sensitivity of echocardiography at rest
was 72.7 % (95 % confidence interval (CI) 0.52–0.88), and specificity was 88.2 % (95 % CI 0.78–0.95). When a cutoff
value for PASP was more than 45 mm Hg during low-dose exercise, SDE missed PH diagnosis in one of the 22
patients with PH and improved sensitivity to 95.2 % (95 % CI 0.81–1.0) but reduced specificity to 84.9 % (95 % CI
0.74–0.93). Reduction of specificity was partly due to concomitant left heart disease.
Conclusions: The results of this prospective cross-sectional study using RHC as gold standard in all patients
showed that SDE markedly improved sensitivity in detecting manifest PH to 95.2 % compared with 72.7 % using
echocardiography at rest only. Thus, for PH screening in patients with SSc, echocardiography should be performed
at rest and during exercise.
Trial registration: ClinicalTrials.gov NCT01387035. Registered 29 June 2011.Introduction
Pulmonary hypertension (PH) is a common complica-
tion of systemic sclerosis (SSc) which can occur at any
stage of the disease and has been observed in 15–27 %
of patients [1, 2]. In most cases, PH is due to pulmonary
arterial hypertension (PAH) which is associated with
SSc (SSc-APAH). Three-year survival for patients with
untreated SSc-APAH has been estimated to be 56 %* Correspondence: ekkehard.gruenig@med.uni-heidelberg.de
1Centre for Pulmonary Hypertension Thoraxclinic, University Hospital
Heidelberg, Amalienstr. 5, 69126 Heidelberg, Germany
Full list of author information is available at the end of the article
© 2015 Nagel et al. This is an Open Access art
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/compared with 91 % in those patients without PAH [3].
According to the french itinerAir study, at PAH diagno-
sis, more than 80 % of patients with SSc are in World
Health Organization (WHO) functional class (FC) II–IV
[4]. Today, 10 PAH-targeted drugs are available for these
patients [5]. Therefore, an early diagnosis of PH/APAH is
essential in patients with SSc.
Echocardiography at rest is the most important non-
invasive method for the detection of PH and has been
recommended for screening of patients at risk in several
guidelines [6–8]. The reliability of tricuspid regurgitation
velocity (TRV) cutoff values, with RHC as a reference,icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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A TRV of at least 3.4 m/s with an assumed right atrial
(RA) pressure of 5 mm Hg (corresponding to a systolic
pulmonary arterial pressure (PASP) of 50 mm Hg) has
been recommended as a cutoff value for performing
RHC to diagnose or exclude PH in the European Society
of Cardiology/European Respiratory Society (ESC/ERS)
guidelines [6]. In a multicenter study aiming at the devel-
opment of a screening algorithm in SSc patients (DE-
TECT study), transthoracic Doppler echocardiography
(TDE) at rest using these cutoff values alone was not reli-
able to detect early forms of SSc-APAH [11]. In this study,
RHC was performed in each patient with SSc. The study
showed that, of 84 patients with manifest SSc-APAH, only
30 % had a TRV of more than 3.4 m/s at rest and 57 % of
more than 2.8 m/s. Thirty-six percent of patients would
have been overlooked if only TDE had been used [11].
When using the screening algorithm of the DETECT
study, including TDE, diffusing capacity of the lung for
carbon monoxide (DLCO), electrocardiogram and further
laboratory parameters, only 4 % of patients were missed
[11]. Previous studies showed that patients with SSc and
increased pulmonary arterial pressure response to exercise
were impaired in their physical exercise capacity [12]. Fur-
thermore, they were more prone to develop a manifest PH
within 1–3 years [13] and had a worse prognosis [14].
Thus, assessing exercise haemodynamics obtained by
RHC and by non-invasive stress Doppler echocardiog-
raphy (SDE) may identify abnormal pulmonary circulation
and may help to identify patients with PH/SSc-APAH at
an early stage [15]. However, the role of SDE for PH
screening is unclear because of the lack of prospective
confirmatory data [6, 7]. Therefore, the objective of this
prospective study was to analyse whether SDE improves
sensitivity and specificity of detecting PH in comparison
with echocardiography at rest. To confirm diagnosis, RHC
at rest and during exercise was performed in all patients.
Methods
Study population and design
The study was designed as a prospective cross-sectional
study in which SSc patients without known PH have
been systematically screened by using echocardiography
at rest, SDE, and RHC [16]. The investigators who per-
formed echocardiography and SDE were blinded to the
results of RHC. To minimise bias, RHC as the confirma-
tory diagnostic test was performed in each patient.
Patients who had diffuse cutaneous systemic sclerosis
(dcSSc) and limited cutaneous systemic sclerosis (lcSSc)
(CREST syndrome) and were at least 18 years old were in-
cluded. Diagnosis of SSc was confirmed by experienced rheu-
matologists (NB, AB, CFie, H-ML, and FS) according to the
standard criteria of the American College of Rheumatology
[17]. Exclusion criteria were the following: manifest PHconfirmed by RHC prior to enrolment, receiving PH ther-
apy, forced vital capacity (FVC) of less than 40 % of pre-
dicted, renal insufficiency, systemic arterial hypertension
with pressure values of more than 160/90 mm Hg at rest
or more than 220/120 mm Hg during exercise despite
optimised medical treatment, previous evidence of clinic-
ally relevant left heart disease, or pregnancy.
All patients underwent a detailed clinical work-up,
including medical history, physical examination, electro-
cardiogram, two-dimensional echocardiography at rest
and during exercise, lung function test, arterial blood
gases, chest x-ray, 6-minute walking distance (6MWD)
under standardised conditions [18], laboratory testing in-
cluding NT-proBNP (N-terminal of the prohormone brain
natriuretic peptide) levels, and RHC. Twelve-lead electro-
cardiogram was performed in all patients (Hellige EK 512 P,
Hellige, Freiburg, Germany). Ventilation/perfusion scintig-
raphy, (Philips Axis, Philips, Hamburg, Germany), com-
puted tomography (Siemens Somatom, Definition AF &
Emotion, Siemens, Berlin and Munich, Germany). Scan of
the lungs, and left heart catheterisation were performed in
all patients with suspected chronic thromboembolic PH,
left heart, or respiratory diseases and when clinically indi-
cated. Manifest PH/APAH has been diagnosed according
to the current ERS/ESC guidelines [6, 7].
Transthoracic Doppler echocardiography at rest
A complete echocardiographic examination was done
prior to exercise. Two-dimensional and colour-flow-guided
continuous-wave Doppler echocardiographic recordings at
rest and during exercise were obtained by experienced
cardiac sonographers (EG and CN) using 3.6–4 MHz
Duplex probes and conventional equipment (Vivid 7, GE
Healthcare, Milwaukee, WI, USA) at rest and during exer-
cise testing as described previously [16]. PASP was esti-
mated from peak tricuspid regurgitation jet velocities
according to the equation: PASP = 4 (V)2 + RA pressure,
where V is the peak velocity (in metres per second) of TRV
[19]. For all calculations, the mean value of at least three
TRV measurements was used. RA pressure was estimated
from characteristics of the inferior vena cava [20]. If it was
less than 20 mm in diameter and decreased during inspir-
ation, we added 5 mm Hg; if it was at least 20 mm, we
added 10 mm Hg.
Stress Doppler echocardiography
Patients were examined on a variable load 45° cycle erg-
ometer (model 8420; KHL Corp., Kirkland, WA, USA)
as described previously [16]. Workload was started at 25
Watts and increased by 25 Watts every 2 min to an
exercise capacity or symptom-limited maximum. TRV,
heart rate, oxygen saturation, and systemic blood pres-
sure were analysed at each stage. Echocardiographic as-
sessment was stored in DICOM (Digital Imaging and
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Right heart catheter
Patients were examined on a variable load supine bicycle
ergometer (model 8420; KHL Corp.) by an experienced
investigator (BE) who was blinded to the results of echo-
cardiography and SDE. The examination at rest was per-
formed as previously described [16] in a supine position
by using the transjugular access with an 8 F introducer
set (MXI100, MEDEX, Smiths Group PLC, London, UK).
Catheterisation was done by triple-lumen 7 F-Swan-Ganz
thermodilution catheters by Edwards Lifesciences (REF:131
F7, Edwards Lifesciences LLC, Irvine, CA, USA). Pressures
were continuously recorded and averaged over several re-
spiratory cycles during spontaneous breathing, both at rest
and during exercise. Cardiac output (CO) was measured
by thermodilution at least in triplicate with a variation of
less than 10 % between the measured values. The zero ref-
erence point for pressure recordings was set at 1/3 of the
thoracic diameter below the anterior thorax surface [21].
After the hemodynamic measurement at rest, the supine
position was changed to a 45° position. The zero reference
point was calibrated to the pulmonary arterial wedge pres-
sure (PAWP). After careful calibration, the hemodynamic
parameters at rest were measured again and the exercise
test was started with a workload of 25 Watts. Workload
was incrementally increased by 25 Watts every 2 min to an
exercise capacity or symptom-limited maximum. All exam-
inations and measurements were performed by the same
experienced team. There were no complications.
Cutoff values of systolic pulmonary arterial pressures at rest
and during mild to moderate exercise
In this study, we used PASPs of more than 40 mm Hg at
rest and of more than 45 mm Hg during low-dose exercise
(25–50 Watts over 2 minutes) as cutoff values for the
non-invasive detection of manifest PH. These thresholds
are based on previous publications, stating that healthy
subjects do not exceed these values at rest [16] or during
low-dose exercise [22] defined as CO below 10 l/min. Fur-
thermore, with the Chemla formula (mean pulmonary ar-
terial pressure (mPAP) = 0.61*PASP + 2 mm Hg) [23] or
the Syyed formula (mPAP = 0.65*PASP +0.55 mm Hg)
[24], which both revealed a high accuracy and precision
[25], mPAP of 25 mm Hg at rest is equal to a PASP of 38
mm Hg, and mPAP of 30 mm Hg during exercise would
reflect a PASP of 45.9 mm Hg. These PASP cutoff values
are also within the recommended values mentioned in the
ERS/ESC guidelines for PH [16].
Ethics statement
This study was conducted in accordance with Good
Clinical Practice and the current version of the revisedDeclaration of Helsinki (World Medical Association
Declaration of Helsinki). The ethics committee of the
University of Heidelberg approved the study (Internal
Ethics-Nr. S-360/2009). Written informed consent was
obtained from each patient prior to enrolment.
Statistical methods
Baseline was defined as the day when the patient under-
went echocardiography at rest and SDE. PH and non-
PH groups were described by using summary statistics:
sample size, mean, and standard deviation for quantitative
data and frequencies (counts and percentages) for qualita-
tive and categorical data. Differences between groups were
analysed with an unpaired two-sided Student’s t test. All
tests were two-sided, and P values of less than 0.05 were
considered statistically significant.
Sensitivity and specificity for echocardiography at rest
and during exercise using cutoff values for PASP of 40
mm Hg at rest and 45 mm Hg during exercise were
calculated separately and in combination of the two
methods compared with RHC as gold standard. We re-
port 95 % confidence intervals (CIs) for sensitivity and
specificity estimates. For the combination of echocardi-
ography at rest and during exercise, a patient was classi-
fied as having PH when being above the threshold for at
least one method. For further analysis of suitability of
the thresholds, receiver operating characteristic (ROC)
and area under the curve estimates with 95 % confidence
intervals are shown. We also performed multiple regres-
sion analysis with stepwise forward selection of parame-
ters for predicting mPAP at rest as metric variable and
also for binary classification of PH (mPAP ≥25 mm Hg
versus mPAP < 25 mm Hg). Parameters included in
multiple regression were age, gender, DLCO (percent-
age), FVC (percentage), systolic pulmonary arterial pres-
sure at rest, at 25 Watts, RA area, right ventricular (RV)
area, and tricuspid annular plane systolic excursion
(TAPSE). All analyses were carried out with IBM SPSS
20 (SPSS Statistics version 20, IBM Corporation,
Armonk, NY, USA).
Results
Study population
During the study, 81 patients with SSc were screened,
and five were excluded for the following reasons: the
diagnosis of SSc was not confirmed in three patients by
an experienced rheumatologist, and two patients were
not willing to perform an RHC. Thus, the final study
group consisted of 76 consecutive patients with SSc: 59 %
(n = 45) of these patients were diagnosed with dcSSc, and
41 % (n = 31) with lcSSc. The mean age was 58±14 years,
and there were 12 (16 %) males and 64 (84 %) females
(Table 1). The youngest patient was 28 years old; the old-
est was 82 years old. The duration of SSc at the time of
Table 1 Characteristics of scleroderma patients
Number of included patients 76
Gender, female/male 64 / 12
Age, years 57.9 ± 14.4
Duration of systemic sclerosis, years 12.0 ± 11.3
Body weight, kg 68.8 ± 14.0
Body height, cm 165.5 ± 8.1
Body surface area, m2 1.8 ± 0.2
WHO functional class
0-I 17 22 %
II 31 41 %
III 27 36 %
6-minute-walking-distance, m 435 ± 94.4
Borg Dyspnoea Scale (6-20) 13.8 ± 2.4
Haemodynamics by right heart catheter
mPAP, mm Hg 20.1 ± 9.6
PVR, dynes*sec per cm5 181.4 ± 151.9
PAWP, mm Hg 8.8 ± 4.9
Cardiac output, l/min 5.4 ± 1.2
Cardiac index, l/min per m2 3.0 ± 0.6
Values are given as number, mean±standard deviation, or number
and percentage
WHO World Health Organization, mPAP mean pulmonary arterial pressure,
PVR pulmonary vascular resistance, PAWP pulmonary arterial wedge pressure
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duration was 16 months. None of these patients had a his-
tory of RHC or targeted oral medication for PH or digital
ulcerations. Clinical findings at baseline are shown in
Table 1.
At baseline, 17 of the 76 patients (22 %) presented
with no signs of dyspnoea in everyday life and during ex-
ercise and therefore were categorized as WHO FC 0-I.
Thirty patients (41 %) were categorized as WHO FC II,
and 27 patients (36 %) as WHO FC III. WHO FC was
not documented in one patient.
Diagnosis of manifest pulmonary hypertension by right
heart catheterisation
Twenty-two (29 %) of 76 patients with SSc had an
elevated mPAP of at least 25 mm Hg and therefore a
manifest PH (Fig. 1). Four of these 22 patients with PH
showed an elevated PAWP of more than 15 mm Hg.
Further diagnostic work-up by left heart catheter re-
vealed a coronary heart disease or left heart failure with
preserved ejection fraction (HFpEF) (or both) in two pa-
tients. Signs of significant pulmonary fibrosis in a CT
scan and an FVC of less than 70 % were found in four
patients with PH. Three patients were classified as hav-
ing PH-interstitial lung disease. One patient presentedwith a PAWP of more than 15 mm Hg and was classified
as having PH with left heart disease after further diag-
nostic work-up, including left heart catheterisation.
In 21 patients (28 %), mPAPs were between 21 and 24
mm Hg at rest (borderline) or more than 30 mm Hg
during exercise or both. In two patients out of this group,
coronary heart disease or HFPEF or both were diagnosed
by left heart catheterisation (Fig. 1). Thirty-three patients
with SSc (43 %) presented with normal mPAP at rest and
during exercise (Fig. 1).
Patients with newly diagnosed manifest PH revealed a
mean mPAP of 33±8 mm Hg and a mean pulmonary
vascular resistance of 339±199 dynes*s per cm5, indicat-
ing an early diagnosis reached by the screening proced-
ure of this study (Table 2).
Comparison between patients without and with
pulmonary hypertension
Patients in the PH group were significantly older with a
later SSc diagnosis and had a higher Modified Rodnan
Skin Score and therefore a more severe skin involvement
(Table 2). Patients with PH had been categorized in
higher WHO FC and revealed significantly lower 6MWD
and a higher Borg Index and NT-proBNP levels than pa-
tients without PH. Patients with PH had a significantly lar-
ger RA and RV area, larger thickness of the free RV wall,
and a lower tricuspid annular plane systolic excursion
than non-PH patients (Table 2). There were no significant
differences between the two groups concerning CO at
rest. During maximum exercise, the PH group showed a
significantly lower CO than the non-PH group and had a
worse RV contractile reserve (Table 2).
Sensitivity and specificity of echocardiography at rest
versus stress Doppler echocardiography during exercise
Echocardiography at rest revealed a sensitivity in diag-
nosing manifest PH of 72.7 % (95 % CI 52–88 %) and a
specificity of 88.2 % (95 % CI 78–95 %) when a cutoff
PASP value of 40 mm Hg was used (Fig. 2a).
SDE with a workload of 25 Watts was possible in 74
(97 %) of the 76 patients. One patient refused exercise
testing; another patient had to miss the exam because of
a foot injury. A further eight patients had to stop exer-
cise testing before cardiopulmonary limitation because
of orthopaedic problems: six patients (7.9 %) had coxar-
throsis or knee arthrosis or both, and two patients (2.6 %)
had knee replacement implants. However, these patients
completed the workload of 25 Watts and could be in-
cluded in the exercise echocardiography analysis.
SDE had a sensitivity in diagnosing manifest PH by
measuring the PASP during low-dose exercise (25 Watt)
of 95.2 % (95 % CI 81–100 %) and a specificity of 84.9 %
(95 % CI 74–93 %) when a cutoff value of more than 45
mm Hg was used (Fig. 2b).
Fig. 1 Results of the screening of 76 patients with systemic sclerosis (SSc) by right heart catheterisation (RHC). This figure shows that within the
screening assessment 29 % of the 76 patients were newly diagnosed with a manifest pulmonary hypertension (PH) and 43 % had no signs of PH.
CHD coronary heart disease, HFpEF heart failure with preserved ejection fraction, mPAP mean pulmonary arterial pressure, PH-ILD pulmonary
hypertension-interstitial lung disease
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most important independent parameter to determine
mPAP (R = 0.856, P > 0.001). For binary classification of
diagnosis of PH, at 25 Watts was the only independent
predictor (R = 0.779, P < 0.001).
The two thresholds, 40 mm Hg PASP at rest and 45
mm Hg PASP during exercise at 25 Watts, were ana-
lysed by ROC analysis for their suitability (Fig. 3). The
cutoff value for echocardiography during exercise at 45
mm Hg revealed the highest combination of sensitivity
and specificity. For the examination at rest, a lower cut-
off value would have led to an increase of sensitivity but
a crucial decrease of specificity.
It was even possible to increase the sensitivity of diag-
nosing a manifest PH by combination of TDE at rest
and during exercise, as shown in Fig. 4 (the squares
symbolize those patients with an invasively diagnosed
manifest PH). With cutoff values of 40 mm Hg for PASP
at rest and of 45 mm Hg at a workload of 25 Watts, 21
out of 22 patients with manifest PH have been identified.
A comparison of different screening algorithms includ-
ing the combination of PASP at rest and at 25 Watts is
given in Table 3.
One patient who would have been missed by the com-
bination of TDE at rest and SDE presented with only a
mild PH with an mPAP of just 26 mm Hg and PASP of
less than 45 mm Hg at rest and during exercise.
Six further patients had PASPs at 25 Watts of more
than 45 mm Hg with an mPAP of less than 25 mm Hg.
These patients were “false-positive” because of elevated
PAWP during exercise. The further diagnostic work-up
showed that two of them had coronary heart disease and
that four had an HFpEF and therefore a post capillary
exercise-induced PH and no PAH.Safety
In the examination by SDE in all patients, TRV could be
successfully measured at rest and during exercise be-
cause of the presence of tricuspid regurgitation in the
enlarged right hearts. SDE and RHC during low work-
loads were safe and could be performed without compli-
cations in all patients.
Discussion
This is the first prospective study evaluating sensitivity
and specificity of echocardiography at rest and during
low-dose exercise (25 Watts, CO <10 l/min) compared
with RHC in patients with SSc. With cutoff values of
PASP of 40 mm Hg at rest and 45 mm Hg during low-
dose exercise, SDE markedly improved the sensitivity to
identify patients with manifest PH (diagnosed by RHC)
from 72.7 % to 95.2 % compared with echocardiography
at rest only. Specificity of PAH diagnosis by SDE was
84.9 % and was reduced mainly because of concomitant
cardiovascular diseases. SDE detected even patients with
only mild manifest PH/PAH-SSc at an early stage (mPAP
of 25–30 mm Hg), which was often overlook by echocar-
diography at rest only. Thus, SDE may be a useful non-
invasive technique to identify SSc patients with PH/PAH
at an early stage.
Pulmonary hypertension screening in systemic sclerosis
patients using transthoracic Doppler echocardiography
at rest
Echocardiography at rest has been used for PH screening
in SSc patients for more than 20 years [26]. However, in
contrast to our study, all previous studies except the DE-
TECT study did not systematically use RHC in all patients.
Denton et al. [27] found a higher sensitivity of 90 % and a
Table 2 Comparison between no pulmonary hypertension and manifest pulmonary hypertension group
Diagnosis No PH Manifest PH
mPAP < 25 mm Hg mPAP ≥ 25 mm Hg
n = 54 n = 22
Mean SD Mean SD P value
Patient characteristics Age, years 54.0 14.4 67.6 8.8 <0.001
Height, cm 167.3 7.8 162.1 8.1 0.02
Weight, kg 70.0 16.0 66.0 10.5 n.s.
Body surface area, m2 1.77 0.2 1.7 0.2 n.s.
Duration of SSc, years 10.7 9.9 15.6 14.4 n.s.
Beginning of SSc, years 44.5 15.0 52.4 16.0 0.04
Modified Rodnan Skin Score 13.3 8.5 18.4 11.4 0.04
6MWD, m 466 77 349 86 <0.001
Borg Dyspnoea 20 13 2 15 2 0.003
WHO FC 0-I 17 (31.5 %) 0
II 26 (48.1 %) 5 (22.7 %)
III 10 (18.5 %) 17 (77.3 %)
Unknown 1 (1.9 %) 0
Laboratory NT-proBNP, pg/mL 290 424 846 773.0 0.02
Blood gas analysis Oxygen saturation, % 96.8 2.1 94.6 3.4 0.01
Lung function Vital capacity, % 95.8 24.2 88.2 29.9 n.s.
FEV1, % 108.0 93.7 83.7 26.9 n.s.
Total lung capacity, % 95.5 21.4 83.8 23.2 0.042
Residual volume, % 2.0 0.8 1.9 0.6 n.s.
Diffusion capacity Diffusion capacity carbon monoxide, % 55.7 13.5 42.1 12.5 <0.001
Echocardio- RV thickness, mm 6.5 1.2 7.6 1.4 0.01
graphy TAPSE, mm 24.0 3.5 20.6 4.0 0.001
RA area, cm2 11.4 3.3 15.5 5.7 <0.001
RV area, cm2 14.6 3.7 17.7 4.2 0.003
TRV, m/s 2.3 0.4 3.4 0.6 <0.001
PASP, mm Hg 25.6 7.3 52.0 18.0 <0.001
PASP max (exercise), mm Hg 49.9 12.7 83.9 18.9 <0.001
Right heart RAP/CVP, mm Hg 3.8 2.6 6.3 4.5 0.02
catheterisation mPAP, mm Hg 14.8 3.4 32.6 7.5 <0.001
at rest PAWP, mm Hg 7.2 3.2 12.4 6.0 0.001
Cardiac output, ml/min 5.6 1.3 5.1 1.0 n.s.
Cardiac index, l/min per m2 3.1 0.6 2.9 0.5 n.s.
PVR, dynes*s/cm5 114 40 339 199 <0.001
During exercise mPAP max, mm Hg 31 7 50 7 <0.001
PAWP max, mm Hg 17 6 21 9 n.s.
Cardiac output max, l/min 11.5 3.4 8.3 2.9 <0.001
PVR max, dynes*s/cm5 96 42 323 207 <0.001
PH pulmonary hypertension, mPAP mean pulmonary arterial pressure, SD standard deviation, SSc systemic sclerosis, 6MWD 6-minute walking distance, WHO FC
World Health Organization functional class, NT-proBNP N-terminal of the prohormone brain natriuretic peptide, n.s. not significant, FEV1 forced expiratory volume
in 1 second, RV right ventricle, TAPSE tricuspid annular plane systolic excursion, RA right atrium, TRV tricuspid regurgitation velocity, PASP systolic pulmonary
arterial pressure, RAP right atrial pressure, CVP central venous pressure, PAWP pulmonary arterial wedge pressure, PVR pulmonary vascular resistance
P values are based on two-sided, unpaired Student’s t tests and Mann-Whitney U test for Borg Dyspnoea Scale score. For Borg Dyspnoea Scale score, median
values equal means. Values are mean±SD. For the category of NT-proBNP, values were missing for 14 patients in the mPAP < 25 mm Hg and eight patients in the
mPAP ≥ 25 mm Hg group. For the category of RV thickness, values were missing for seven patients for each group. For the categories of RA area, RV area, and
TRV, values for one patient were missing in the mPAP < 25 mm Hg group. For the category of PASP, values were missing for three patients in the mPAP < 25 mm
Hg group. For the category of PASP max (exercise), values were missing for three patients in the mPAP < 25 mm Hg group. For the categories of cardiac index,
mPAP max, PWAP max, cardiac output max, and cardiac index max, values for one patient was missing for each group, respectively
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Fig. 2 a Correlation of systolic pulmonary arterial pressures (PASP) determined by echocardiography and mean pulmonary arterial pressure (mPAP) at
rest. The x-axis shows the PASP values measured by echocardiography at rest, the y-axis the values measured by right heart catheterisation (RHC). The
values of each patient are given in red, indicating that the assessment including RHC diagnosed a manifest pulmonary hypertension (PH) with an
mPAP at rest of at least 25 mm Hg. The symbols in green are the values of systemic sclerosis patients with no manifest PH at rest. As cutoff value for
the PASP, 40 mm Hg at rest was used. The sensitivity was 72.7 % (95 % confidence interval (CI) 52–88 %) and the specificity was 88.2 % (95 % CI 78–95
%) in diagnosing a PH (P < 0.001). There was a positive correlation (r = 0.860) between PASP and mPAP. b Correlation of PASP at 25 Watts and mPAP
at rest. The x-axis shows the PASP values measured by echocardiography during low-dose exercise at 25 Watts. The y-axis shows the values measured
by RHC at rest. Sensitivity was 95.2 % (95 % CI 81–100 %) and specificity was 84.9 % (95 % CI 74–93 %) in diagnosing a PH using a cutoff PASP value of
45 mm Hg at 25 Watts (P < 0.001). Positive correlation (r = 0.860) between PASP at 25 Watts and mPAP
Fig. 3 Receiver operating characteristic (ROC) curves of sensitivity
and specificity of systolic pulmonary arterial pressures (PASP) at
rest and at 25 Watts. The threshold for detection of pulmonary
hypertension was set at 40 mm Hg for echocardiography at rest and
at 45 mm Hg for echocardiography during exercise. All possible
thresholds were analysed by ROC analysis for their suitability. The
cutoff value for echocardiography during exercise at 45 mm Hg
revealed the highest combination of sensitivity and specificity. For
the examination at rest, a decrease of the cutoff value would have
led to an increase of sensitivity but a crucial decrease of specificity.
AUC area under the curve, CI confidence interval
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fied manifest SSc-APAH by RHC in 64 % of patients.
However, this was a highly pre-selected patient cohort. In
our prospective study, patients have been consecutively
included even when they had no symptoms. Mukerjee
et al. [9] described sensitivity and specificity values accord-
ing to different cutoff values of PASP at rest of at least 30
mm Hg, at least 35 mm Hg, at least 40 mm Hg, and at
least 45 mm Hg of 88/42 %, 75/66 %, 58/87 %, and 47/97
%, respectively. Their conclusion was that TDE at rest is
not a useful screening tool for early SSc-APAH but may
provide a moderate specificity in advanced PAH. Hsu
et al. detected a sensitivity of TDE diagnosing PH in a
high-risk cohort of patients with symptomatic SSc (49 %
were diagnosed with PH) of 58 % using a cutoff level of
47 mm Hg [28]. These previous findings are in contrast
to those of the DETECT study, in which RHC was per-
formed in each patient with SSc. Of the 85 patients with
manifest SSc-APAH, only 29.8 % had a TRV of at least
3.4 m/s at rest corresponding to a cutoff PASP value of
50 mm Hg [11]. Thirty-six percent of patients with
manifest PH would have been overlooked using TDE at
rest only [11] using a cutoff value of 2.8 m/s corre-
sponding to 40 mm Hg at rest. The results of the DE-
TECT study have been confirmed in a retrospective
Fig. 4 Correlation of systolic pulmonary arterial pressure (PASP) at
25 Watts and PASP at rest. Cutoff values are 45 mm Hg for PASP at
25 Watts and 40 mm Hg PASP at rest. Circles represent patients
without pulmonary hypertension (PH) verified by right heart
catheterisation (RHC); squares are patients with manifest associated
pulmonary arterial hypertension according to RHC as gold standard.
PASP at rest with a cutoff value of 40 mm Hg would have missed
five manifest PH patients; PASP at 25 watts with a cutoff value of 45
mm Hg would have missed only one patient with a slightly lower
specificity. CI confidence interval
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for TRV would have been missed in 48 % of patients
[29]. The sensitivity of TDE at rest in our study was
higher and this might be because the DETECT study
presented a “real-world” echocardiographic assessment
without clear pre-evaluation of investigators and train-
ing of this method. In contrast, in our study, TDE wasTable 3 Comparison of screening algorithms for pulmonary hyperte
Approach False negatives, %
(missed diagnoses)
S
SDE at rest and during exercise 1 9
N = 76
DETECT algorithm 4 9
N = 319
DETECT algorithm with 15 8
65 % specificity at step 2
N = 319
DETECT data with algorithm from
ESC/ERS guidelines* 29 7
N = 371
PPV positive predictive value (confirmed pulmonary arterial hypertension out of all
Doppler echocardiography, ESC/ERS European Society of Cardiology/European Resp
Adaptation of the table provided by Coghlan et al. [11] in the DETECT study
*Evaluated on a subset of patients from DETECT study (n = 371) with available data
Criteria were the following: (a) tricuspid regurgitant jet velocity >3.4 m/s or (b) tricu
least one of the following DETECT parameters: current anginal pain, current syncop
tricuspid regurgitant jet velocity ≤2.8 m/s AND symptomatic (defined as above) AN
hypertension (defined as right atrium area >16 cm2 or ratio of right ventricular diammore standardised. The results of our study suggest that
accuracy of TDE could probably increase even more if
further parameters such as RA and ventricular area
were included. This was also recommended in the
Delphi consensus study [30]. The current recommenda-
tion from the Scleroderma Foundation and Pulmonary
Hypertension Association for screening of PH [31] is to
use a combination of DLCO, TDE (both high evidence),
NT-proBNP, and the DETECT algorithm if DLCO% is
less than 60 % and disease duration is more than 3 years
(both moderate evidence) [11].
Role of stress Doppler echocardiography in the screening
for pulmonary hypertension in patients with systemic
sclerosis
Within the last 10 years, SDE has been increasingly used
to assess pulmonary circulation [15]. Alkotob et al.
(2006) reported for the first time that a PASP increase
more than 40 mm Hg during exercise was associated
with a higher risk of developing manifest PH [13]. Fur-
thermore, patients with exercise-induced PH reached
lower workloads [12] and exercise time [13]. Steen et al.
(2008) identified 17 out of 21 patients with ΔPASP in-
crease of more than 20 mm Hg during exercise and sug-
gested that these patients are at risk for PH [32]. All of
these patients were symptomatic, but only 19 % of pa-
tients had a manifest PH according to the current defin-
ition (mPAP of at least 25 mm Hg). Kovacs et al. (2010)
showed a close correlation between pulmonary artery
pressures (PAPs) obtained by SDE and RHC during exer-
cise and confirmed less 6MWD in patients with SSc-
APAH [12]. Codullo et al. (2013) demonstrated, in ansion in systemic sclerosis
ensitivity, % Specificity, % PPV, % NPV, %
6 82 68 98
6 48 35 98
5 72 47 94
1 69 40 89
right heart catheterization referrals), NPV negative predictive value, SDE stress
iratory Society
for the variables defined in the guideline
spid regurgitant jet velocity >2.8 to ≤ 3.4 m/s AND symptomatic (defined as at
e/near syncope, current dyspnoea, or presence of peripheral oedema) or (c)
D presence of additional echocardiography variables suggestive of pulmonary
eter/left ventricular end diastolic diameter >0.8 or both)
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during SDE is a risk factor for the development of mani-
fest PH [33]. All of these studies showed certain aspects
of SDE and identified elevated PASP during exercise as a
risk factor for the development of pulmonary vascular
disease. However, none of these studies assessed sensitiv-
ity and specificity of this method in identifying PH using
RHC as the gold standard in all patients. Our results in-
dicate that SDE can be a reliable non-invasive screening
method for early manifest PAH in SSc if the assessment
is standardised. There are the first data indicating that
an early treatment with PH-targeted therapy might at-
tenuate PASP increase in patients with borderline PH in
SSc [34]. However, the role of early treatment in SSc-
APAH is still to be investigated by randomised con-
trolled trials.
Which cutoff value for systolic pulmonary arterial
pressures is useful?
The current ESC/ERS guidelines did not recommend
SDE [6] and this was due mainly to the lack of agree-
ment on cutoff values for PASP during exercise. A PASP
of 40 mm Hg is usually taken as the upper limit of nor-
mal [4, 35–37], even though this value may be exceeded
during exercise by athletes with a CO far above 10 l/min
[38]. Therefore, assessment of exercise-induced increases
in PAPs should be interpreted relative to increases in
blood flow (i.e., ΔPASP/ΔCO) and specific work rates ra-
ther than relying on a single absolute PASP or mPAP
threshold or a peak exercise PAP [15, 39, 40]. Therefore,
in this study, we used PASPs of 40 mm Hg at rest and of
45 mm Hg during low-dose exercise (25 Watts) with
COs clearly less than 10 l/min as cutoff values. This is in
line with previous data in healthy subjects [16, 38] and
methodological prediction formulas (Syyed and Chemla)
of PAP [23–25].
Limitations
Results of SDE can be affected by concomitant diseases
such as left heart disease or lung diseases. In our study,
the presence of left ventricular dysfunction associated with
high PAWP led to false-positive results in SDE [41, 42].
Therefore, in all patients with elevated PAP and high sys-
temic blood pressures or pulmonary artery wedge pres-
sures, a left heart catheterisation has been performed.
Furthermore, in any screening program, it cannot be
excluded that there is a referral bias due to the fact that
predominantly those patients are willing to perform the
screening who already feel some symptoms. Nevertheless,
we have included consecutive patients despite symptoms
which resulted in a high proportion of patients (22 %) with
no or only mild symptoms in our cohort.
TDE and SDE are somewhat dependent on experi-
enced investigators and standardisation of the procedure.Thus, these results may not present a non-standardised
screening process. In general, standardisation might be
necessary and useful when screening SSc patients for
PH. The underlying disease, especially in the case of
dcSSc with interfering musculoskeletal involvement, may
have influenced the results of the exercise test. The par-
ameter of PASP during exercise in this study corre-
sponds to a workload of 25 Watts. An impaired exercise
capacity is therefore assumed to have no crucial impact
on the results.
Conclusions
The results of this prospective cross-sectional study using
RHC as gold standard in all patients showed that SDE
markedly improved sensitivity in detecting manifest PH to
95.2 % compared with 72.7 % in echocardiography at rest
in patients with SSc. Thus, for PH screening in patients
with SSc, it might be useful to perform echocardiography
at rest and during exercise.
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